Rosacea-Treatment Patent Licensed to Quick-Med Technologies

Sponsored Links

A Florida-based biotechnology company Quick-Med Technologies Inc., is the licensee of a newly issued patent for the treatment of rosacea. Rosacea is a disease of unknown origin, which is characterized with chronic inflammation of the cheeks, nose, chin, forehead and eyelids. About 16 million people in the U.S., mainly women between 30 and 60 years of age suffer from rosacea. The related patent covers the method of treating the disorder with a group of compounds known as matrix metalloproteinase inhibitors. These are also used to treat skin damage due to aging or sun exposure, or for exposure to sulfur mustard gas following a terrorist attack. The patent was issued to the University of Michigan, this Sept. 14 which in turn licensed it to Quick-Med. Professor Sewon Kang, who is the chairman of the department of dermatology at Johns Hopkins University's Medical School is the lead inventor of this patent. (Source:

About the Author

Sanjay Patel's picture
Author: Sanjay Patel

You May Also Like..